IBA Molecular, North America has a well-established Compliance Program that reflects IBA Molecular's commitment to comply with the laws and regulations that govern pharmaceutical marketing and selling activities in the United States.
Although IBA Molecular is not a typical pharmaceutical manufacturer, it has still created the IBA Molecular's Compliance Program that is consistent with the recommendations set forth in "Compliance Program Guidance for Pharmaceutical Manufacturers," published by the Office of Inspector General, U.S. Department of Health and Human Services (the "HHS-OIG Guidance") and the provisions of the Code on Interactions with Healthcare Professionals created by the Pharmaceutical Research and Manufacturers of America ("PhRMA Code").
The goal of IBA Molecular's Compliance Program as a Radiopharmaceutical Manufacturer is to maintain a culture that promotes the prevention, detection and resolution of potential violations of law or Company policy.
IBA Molecular's Compliance Program is dynamic, involving regular assessment and adjustment to ensure the Program is responsive to the Company's evolving business and associated compliance risks.
For further information, IBA Molecular, North America's Compliance Officer, Michelle Ernsdorff at michelle.ernsdorff@iba-group.com.
